FRISS
29.10.2020 07:58:08 CET | Business Wire | Press release
Grupo Ageas Portugal, serving approximately 1.7 million clients with 1,281 employees and via 2,722 agents, announced today that they have selected FRISS Fraud Detection at Claims in order to streamline their digital claim handling and prevent and protect their customers from fraud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005826/en/
The real-time FRISS solution provides a unique combination of out-of-the-box risk and fraud indicators with powerful AI techniques such as predictive models, network analysis, and text mining. With this flexible and future-proof claims fraud solution, Grupo Ageas Portugal will further drive its digital transformation and safely streamline operations. Its customers can be helped with service beyond insurance, while high risks will be automatically flagged for further investigation.
The FRISS solution is pre-integrated with Duck Creek Claims . In order to provide a seamless experience for their claim adjusters, Grupo Ageas Portugal will be using the Anywhere Enabled Integration for this solution available in Duck Creek’s Content Exchange . Besides delivering fast customer service for the insurer’s clients, this will also limit the amount of false positives, giving employees time to focus on their customers. This is a great example of a technology-driven partnership in innovation.
Sjoerd Smeets, Chief Risk Officer at Grupo Ageas, said: "With the choice of FRISS, we have opted for a company fully dedicated to fraud prevention. During the selection process, they have shown their industry knowledge, good technical solutions, and especially agility. We are confident that with FRISS we will detect more fraud, handle claims faster, and provide higher quality for our customers."
Ariane Braam-Verkoren, Global Alliance Manager at FRISS, added, “In my journey at FRISS to expand our business to many new territories in the world, I’m excited to see so many insurers join our quest for honest insurance. We are proud to have Grupo Ageas on board and to be their partner of choice in the fight against fraud in Portugal.”
“To offer the best in risk and fraud detection to our customers, it was critical for us to align with a partner like FRISS,” said Juan Antonio Costa, Country Manager for Spain & Portugal at Duck Creek Technologies. “Their solution employs ultra-modern technologies like machine learning and AI, and Grupo Ageas Portugal made an excellent choice for their customers and for the efficiency of their organization by rapidly executing this step in their digital transformation.”
FRISS Fraud Detection at Claims will be implemented at Grupo Ageas Portugal’s Motor, Property, WMC (Workers’ Compensation), and Personal Accidents lines of business.
About Grupo Ageas Portugal
Founded in 1824, Ageas is an international insurance group based in Brussels and present in 14 countries in Europe and Asia. Operating in Portugal since 2005, Ageas invests in the country as one of the main markets, where it intends to develop, through strong partnerships and contributing to the development of the country and society through the Ageas Foundation and helping Clients to manage, anticipate and protect yourself against risks and unforeseen circumstances, so that you can live the present and the future with maximum security and serenity. The Ageas Portugal Group's mission is to provide an emotional and relevant experience in people's lives, being a reference partner in insurance and the best workplace for entrepreneurial people. To this end, we have 1,281 Employees and 2,722 Mediators to provide an excellent service to the approximately 1.7 million Customers of the various commercial brands: Ageas Seguros, Ageas Pensões, Médis, Ocidental and Seguro Directo. In order to diversify the business and be close to its customers, the Ageas Portugal Group goes beyond insurance, offering a wide range of services through the Clínica Médis, Kleya, Go Far, Ageas Repara and Mundo Ageas. For more information, you can visit the website , or follow us on Linkedin and Instagram .
About Duck Creek Technologies:
Duck Creek Technologies is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand , the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally rich solutions are available on a stand-alone basis or as a full suite , and all are available via Duck Creek OnDemand. For more information, visit www.duckcreek.com .
About FRISS
FRISS is 100% focused on automated fraud and risk detection for P&C insurance companies worldwide. Their AI-powered detection solutions for underwriting, claims and SIU help 175+ insurers grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 4 months, realize up to 10 times ROI and 80% increase in straight through processing of policy application and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth, and improve the customer experience. For more information, please visit www.friss.com or Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005826/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom